Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 10:12:51 2024-05-17 am EDT			5-day change	1st Jan Change
2.82 ^USD	-2.76%		-32.91%	-41.37%

May. 15	Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating	MT
May. 14	Top Midday Decliners	MT

Akoya Biosciences, Inc. Provides Revenue Guidance for the Year 2022

November 07, 2022 at 04:05 pm EST

Akoya Biosciences, Inc. provided revenue guidance for the year 2022. The Company, based on its updated plans and initiatives, is raising its full year 2022 revenue guidance range to $73 million to $75 million.

Latest news about Akoya Biosciences, Inc.

Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating	May. 15	MT
Top Midday Decliners	May. 14	MT
Top Premarket Decliners	May. 14	MT
Exchange-Traded Funds Mixed, Equity Futures Higher Pre-Bell Tuesday Ahead of Powell Speech	May. 14	MT
Akoya Biosciences Sinks Over 30% in Late-Hours Activity Monday as Q1 Sales Miss Capital IQ Estimate	May. 14	MT
Transcript : Akoya Biosciences, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q1 Revenue $18.4M, vs. Street Est of $24.3M	May. 13	MT
Akoya Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Akoya Biosciences, Inc. and NeraCare Enters into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients	May. 09	CI
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts	May. 06	CI
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows	May. 02	CI
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale	Apr. 05	CI
JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating	Mar. 06	MT
UBS Adjusts Akoya Biosciences Price Target to $7.50 From $7, Maintains Buy Rating	Mar. 05	MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	Mar. 04	CI
Transcript : Akoya Biosciences, Inc., Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q4 Revenue $26.5M, vs. Street Est of $26.1M	Mar. 04	MT
Akoya Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 04	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Transcript : Akoya Biosciences, Inc. - Special Call	Feb. 28
Transcript : Akoya Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Akoya Biosciences, Inc. Announces Board Changes	Jan. 10	CI
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal	Jan. 08	DJ
Akoya Biosciences Expects 20% Revenue Growth in 2024; Shares Gain Premarket	Jan. 08	MT
Akoya Biosciences Unveils Algorithm for Integration of Spatial, Single-Cell Data; Shares Jump Premarket	Jan. 08	MT

Chart Akoya Biosciences, Inc.

Duration

Period

More charts

Company Profile

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-04 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Akoya Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.9 USD

Average target price

7.429 USD

Spread / Average Target

+156.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AKOYA BIOSCIENCES, INC.	-41.37%	143M
THERMO FISHER SCIENTIFIC	+11.84%	228B
DANAHER CORPORATION	+14.17%	196B
INTUITIVE SURGICAL, INC.	+17.38%	141B
BOSTON SCIENTIFIC CORPORATION	+28.85%	110B
SIEMENS HEALTHINEERS AG	+1.03%	65.88B
EDWARDS LIFESCIENCES CORPORATION	+17.82%	54.3B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.63%	52.39B
AGILENT TECHNOLOGIES, INC.	+11.09%	45.22B
GE HEALTHCARE TECHNOLOGIES INC.	+4.64%	37.12B

Other Advanced Medical Equipment & Technology